206 related articles for article (PubMed ID: 21846819)
1. Autoantibodies to mesothelin in infertility.
Luborsky JL; Yu Y; Edassery SL; Jaffar J; Yip YY; Liu P; Hellstrom KE; Hellstrom I
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1970-8. PubMed ID: 21846819
[TBL] [Abstract][Full Text] [Related]
2. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
[TBL] [Abstract][Full Text] [Related]
3. Anti-HE4 antibodies in infertile women and women with ovarian cancer.
Hellstrom I; Swisher E; Hellstrom KE; Yip YY; Agnew K; Luborsky JL
Gynecol Oncol; 2013 Sep; 130(3):629-33. PubMed ID: 23727327
[TBL] [Abstract][Full Text] [Related]
4. Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure.
Edassery SL; Shatavi SV; Kunkel JP; Hauer C; Brucker C; Penumatsa K; Yu Y; Dias JA; Luborsky JL
Fertil Steril; 2010 Dec; 94(7):2636-41. PubMed ID: 20522323
[TBL] [Abstract][Full Text] [Related]
5. Association of unexplained infertility with gonadotropin and ovarian antibodies.
Shatavi SV; Llanes B; Luborsky JL
Am J Reprod Immunol; 2006; 56(5-6):286-91. PubMed ID: 17076672
[TBL] [Abstract][Full Text] [Related]
6. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients.
Hellstrom I; Friedman E; Verch T; Yang Y; Korach J; Jaffar J; Swisher E; Zhang B; Ben-Baruch G; Tan MC; Goedegebuure P; Hellstrom KE
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1520-6. PubMed ID: 18559570
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
Ho M; Hassan R; Zhang J; Wang QC; Onda M; Bera T; Pastan I
Clin Cancer Res; 2005 May; 11(10):3814-20. PubMed ID: 15897581
[TBL] [Abstract][Full Text] [Related]
8. Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population.
Luborsky J; Llanes B; Davies S; Binor Z; Radwanska E; Pong R
Clin Immunol; 1999 Mar; 90(3):368-74. PubMed ID: 10075866
[TBL] [Abstract][Full Text] [Related]
9. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Hassan R; Remaley AT; Sampson ML; Zhang J; Cox DD; Pingpank J; Alexander R; Willingham M; Pastan I; Onda M
Clin Cancer Res; 2006 Jan; 12(2):447-53. PubMed ID: 16428485
[TBL] [Abstract][Full Text] [Related]
10. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
11. [Mesothelin in ovarian cancer].
Fraszczak K; Barczyński B; Polak G; Kułak K; Kotarski J
Pol Merkur Lekarski; 2013 Sep; 35(207):166-70. PubMed ID: 24224456
[TBL] [Abstract][Full Text] [Related]
12. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
14. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
Scholler N; Fu N; Yang Y; Ye Z; Goodman GE; Hellström KE; Hellström I
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11531-6. PubMed ID: 10500211
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
16. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
[TBL] [Abstract][Full Text] [Related]
17. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
[TBL] [Abstract][Full Text] [Related]
18. Anti-endometrial autoantibodies in women with a diagnosis of infertility.
Palacio JR; Iborra A; Gris JM; Andolz P; Martínez P
Am J Reprod Immunol; 1997 Aug; 38(2):100-5. PubMed ID: 9272208
[TBL] [Abstract][Full Text] [Related]
19. Anti-ovarian antibodies in sera of patients with ovarian tumors.
Szubert S; Michalak S; Szpurek D; Moszynski R; Krygowska-Zielinska J; Sajdak S
Immunol Lett; 2012 Dec; 148(2):133-7. PubMed ID: 23026238
[TBL] [Abstract][Full Text] [Related]
20. The value of mesothelin in the diagnosis and follow-up of surgically treated ovarian cancer.
Qiao N; Li H
Eur J Gynaecol Oncol; 2013; 34(2):163-5. PubMed ID: 23781590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
